Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study
Background Ocrelizumab, a humanised anti-CD20 monoclonal, is a highly effective treatment for relapsing-remitting multiple sclerosis (RRMS). The long-term safety of B-cell depletion in RRMS, however, is uncertain and there are no data on dose reduction of ocrelizumab as a risk mitigation strategy. T...
| Príomhchruthaitheoirí: | , , , , , |
|---|---|
| Formáid: | Alt |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
BMJ Publishing Group
2024-06-01
|
| Sraith: | BMJ Neurology Open |
| Rochtain ar líne: | https://neurologyopen.bmj.com/content/6/1/e000672.full |